Case Study

Infinitopes

Saving lives with precision cancer immunotherapy

Play the video Read More
Date posted: 07/08/2025

The mission of Oxford-based, Cancer Research UK spin-out, Infinitopes, is to prevent cancer deaths by tackling the leading cause: Metastases.

The challenge

70-90% of cancer deaths, more than 10 million every year, are caused by metastases, when tumours spread from the original site. Infinitopes has developed technologies to hunt down metastases, to stop cancers from coming back.

The approach

The company leverages advanced, bespoke AI-guided discovery platforms capable of screening patient tumours to accurately identify target proteins that are uniquely on the surfaces of cancer cells. Infinitopes can then engineer proprietary, precision vaccines to attack those target ‘epitopes’ stimulating long-lasting protection.

Infinitopes’ vaccine-educated immune cells are extraordinarily efficient at seeking and destroying tumours. Patients’ immune systems become trained to provide whole-body surveillance, safely eliminating future metastases, to prevent cancers from recurring.

Because of its world-leading discovery technologies, Infinitopes can design vaccines ahead of time, to be available early to newly diagnosed patients, avoiding the costs, delays and clinical complexities of competing systems.

The company aims to do this again and again, cancer by cancer, for an infinite number of epitope targets, hence their name, Infinitopes.

Innovate UK’s role

Infinitopes received Innovate UK funding through the Investor Partnership Programme, which was pivotal to building and testing their cutting-edge discovery platform, and the Cancer Therapeutics Programme, to design, prepare and execute its phase I clinical trial, that scientists hope will be practice-changing. That phase I is scheduled to begin dosing in quarter three 2025, with results anticipated by quarter two in 2026.

We’re grateful to Innovate UK because the two awards that we won let us do two very exciting things. The first, for our Precision Immunomics group, has allowed us to enhance our technologies to identify safe and effective targets on the outside of tumour cells. And we literally do that better than anyone else on the planet, because of Innovate UK’s support.

Once we’d achieved that, we were able to take several of those into our phase I/IIa clinical trial, designed to test safety, and also that these vaccines stimulate strong, durable, lasting immunity, to protect patients from their cancers. Those two projects are directly as a result of these grants.

Dr Jonathan Kwok, CEO and Co-founder

Related Content

Sector

This Case Study is part of Health.

Health is critical to our wellbeing as individuals, plays a key role in societal and economic advances, and presents many opportunities for environmental impact. Innovations in health & care allow us to alleviate suffering, increase quality of life and life expectancy, and manage the needs of a changing and ageing population.

Find out more
Close

Connect with Innovate UK Business Connect

Join Innovate UK Business Connect's mailing list to receive updates on funding opportunities, events and to access Innovate UK Business Connect's deep expertise. Please check your email to confirm your subscription and select your area(s) of interest.